

CURRICULUM VITAE

DATE: October 1 2016

NAME: George P. Studzinski, M.D., Ph.D

PRESENT TITLE: Professor

OFFICE ADDRESS: Department of Pathology and Laboratory Medicine
New Jersey Medical School, (NJMS), Rutgers University
185 South Orange Avenue - C543
Newark, New Jersey 07103-2714
Tel: (973) 972-5869
Fax: (973) 972-7293

TELEPHONE NUMBER/E-MAIL ADDRESS: 973-972-5869 / STUDZINS@NJMS.RUTGERS.EDU

CITIZENSHIP: USA

EDUCATION:

A. Undergraduate Graduate and Professional

University or College: University of Glasgow, Scotland
City, State Glasgow, Scotland
Degree B.Sc. First Class Honors in Biochemistry
Date Awarded 1955

B. Graduate and Professional

- 1) *University or College:* University of Glasgow, Scotland
City, State Glasgow, Scotland
Degree (Discipline) M.B. Ch.B. Medicine, University of Glasgow (Equivalent of MD)
Date Awarded 1958
- 2) *University or College:* University of Glasgow, Scotland
City, State Glasgow, Scotland
Degree (Discipline) Ph.D. (Experimental Pathology)

POSTGRADUATE TRAINING:

A. Internship and Residencies

Location: Stobhill Hospital, Glasgow Scotland
Discipline: Internal Medicine Internship
Inclusive Dates: July 1958 Dec 1958

Location: Western Infirmary, Glasgow Scotland
Discipline: General Surgery internship
Inclusive Dates: Jan 1959- June 1959

Location: Royal Infirmary, Glasgow Scotland
Discipline: General Surgery Residency
Inclusive Dates: July 1959- July 1962

B. Research Fellowships

British Empire Cancer Fellowship
Location : Royal Infirmary Glasgow Scotland
Inclusive Dates: Overlapping with the last year of Residency

MILITARY: *None*

ACADEMIC APPOINTMENTS:

1962-76 *Instructor to Professor of Pathology, Jefferson Medical College, Philadelphia, PA.*
1976-83 *Professor and Chairman, Department of Pathology, UMDNJ-NJ Medical School*
1983-present *Professor of Pathology & Laboratory Medicine, UMDNJ (now Rutgers)-New Jersey Medical School*
2014- present *Program Advisory Committee of the International Vitamin D Workshop*

HOSPITAL APPOINTMENTS:

Attending Physician
Newark University Hospital
Jan 1976- present

OTHER EMPLOYMENT OR MAJOR VISITING APPOINTMENTS: *None*

PRIVATE PRACTICE *None*

LICENSURE: *Medical Doctor expires 6/30/2017*

DRUG LICENSURE:

CDS: *D01824400-10/31/2016*

DEA: *AS66605909 10/31/2016*

CERTIFICATION: *specialty/#/expiration*

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

1972-77 *Scientific Advisory Committee, Damon Runyon-Walter Winchell Cancer Fund*
1973-77 *NIH Pathology B Study Section*
1995-present *Special Projects Study Sections, NIH*
1999-present *Pool of Reviewers, NCI*
2015 *The most recent participation in NCI review panel - June 2015 BMCT Study Section*
1972-77 *Scientific Advisory Committee, Damon Runyon Walter-Winchell Cancer Fund*
1973-77 *NIH Pathology B Study Section*
1978-1995 *Advisory Board, CIDAC-Carcinogenesis, Cancer Biology, Cancer Therapy (NCI-sponsored publications)*
1983-present *Editorial Advisory Board of Exp Cell Res, Critical Reviews in Clinical Laboratory Science*
1990-1991 *President Elect, Cell Kinetics Society*
1973-78 *President, Cell Kinetics Society*
1992-2003 *AACR NJ State Legislative Committee*
1994 *Appeals Review Board, NIH*
1977-present *NIH Site Visits and ad hoc participations in various NCI Study Sections.*
1995-present *Special Projects Study Sections, NIH*
1999-present *Pool of Reviewers, NCI*
2006-2009 *Regular member of NCI study Section-Subcommittee F (Career Development Awards and Cancer Training Programs).*
2011 *NCI SPORE in Mesothelioma, Lung, Breast and Ovarian Cancers SEP*

2011 "MicroRNA" Editorial Board member
2014- present Program Advisory Committee of the International Vitamin D Workshop
2015. The most recent participation in NCI review panel - June 2015 BMCT Study Section

HONORS AND AWARDS:

1990-1991 President Elect, Cell Kinetics Society
1994 Alfred Jurzykowski Award in Medicine

BOARDS OF DIRECTORS/TRUSTEES POSITIONS: None

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

SERVICE ON MAJOR COMMITTEES:

See above. Ad hoc reviewer for over 20 Journals

SERVICE ON GRADUATE SCHOOL COMMITTEES:

Multiple over the years
1977-78 Chairman, Microbiology Search Committee, NJMS
1977-79 Chairman, Committee on Academic Policies & Promotions, NJMS
1980-82 Chairman, Committee of Continuing Education
1982 Member, Committee on Cancer Education
1984-89 Member, Committee on Graduate Studies in Exp Pathology
1986-88 Member, Faculty Committee on Appointments & Promotions
1987 Member, Operational Committee, NJ Cancer Center
1987 Director, Graduate Course "Tumor Cell Biology"
1988-92 Director, Pathology Course for Medical Students
1991 Member, Standing Committee on Termination for Cause
1994 Subcommittee for Arts and Sports Events, 40th Anniversary Celebration
1997 Race & Walk Committee, NJMS
2000-2001 Chair, Search Committee for Director of New Jersey Medical School Cancer Center

SERVICE ON HOSPITAL COMMITTEES: Currently none

SERVICE TO THE COMMUNITY : Many years President of Running Clubs.
Director of an Annual Swim- Run Biathlon

TEACHING RESPONSIBILITIES:

1. Director of the Course: General Pathology for Graduate Students, PATH 5010
- 2 Lectures to Medical students in the First and Second Years
3. Lectures to Dental students in the First and Second Years
- 4.Lectures to Post Grad Dental PGY1

CLINICAL RESPONSIBILITIES: Attending Physician –Formerly Director of Laboratories

GRANT SUPPORT:

A. **Ongoing Research Support**

Principal Investigator

1. 5RO1-044722 -26 Studzinski (PI) 06/01/1987 - 01/31/2017

“Vitamin D Analogs as Adjuvants in Chemotherapy of Cancer”. NIH/NCI

This project evaluates the role of vitamin D analogs in differentiation and in induction of cell death of human leukemia cells in established and in primary culture. Mechanisms studied focus on the various branches and regulators of MAPK pathways to provide guidelines for future therapeutic approaches.

It is currently approved for funding through year 26 of the grant.

Role: PI

2. *Fellowship to Ruifang Zheng, MD, PhD from the New Jersey Commission on Cancer Research
Jan 1, 2015- Dec 31, 2016.*

Role : Mentor

A. Pending

A competitive renewal of 5R01-044722, listed above. The current application has the same overall goal, and there is overlap with Aim 2a of the R01.No overlap with other Aims. No intent to duplicate support.

Grant History

This investigator has been funded by NIH/NCI since 1972. Also held grants from the American Cancer Society, Susan Komen Foundation, the Bi-National Israel-USA Science Foundation, the American Institute for Cancer Research, and other granting agencies.

B. Co-Investigator

None

C. Pending See above

D. PUBLICATIONS:

Also available at <http://www.ncbi.nlm.nih.gov/pubmed/?term=studzinski+GP>.

Original Reports:

1. **Studzinski GP**, Symington T and Grant JK: Triphosphopyridine nucleotide linked dehydrogenases in the adrenal cortex in man; the effect of corticotrophin and the distribution of enzymes. *Acta Endocrinologica*, 40:232-246, 1962.
2. **Studzinski GP** and Grant JK: Effect of adenosine-3', 5'-phosphate on corticosteroid production in vitro by slices of the adrenal cortex of human beings. *Nature*, 193:1075-1076, 1962.
3. **Studzinski GP**, Hay DCF and Symington T: Observations on the weight of the human adrenal gland and the effect of preparations of corticotropin of different purity on the weight and morphology of the human adrenal gland. *J Clinical Endocrinology Metabolism*, 23:248-254, 1963.
4. **Studzinski GP** and Love R: Accumulation of acid-soluble nucleic acid precursors in HeLa cells inhibited by 5-fluoro- 2'- deoxyuridine. *Exp. Cell. Res.*, 32:190-192, 1963.
5. Love R, Clark AM and **Studzinski GP**: Cytochemical studies on deoxyribonucleic acid mediated control of ribonucleoprotein metabolism. *Nature*, 203:1384, 1964.

6. **Studzinski GP** and Love R: Effects of puromycin on the nucleoproteins of the HeLa cell. *J Cell Biol*, 22:493-503, 1964.
7. **Studzinski GP** and Love R: Nucleolar organelles shown by lead precipitation in unfixed cultured cells. *Stain Technology*, 39:397-401, 1964.
8. **Studzinski GP**: Nucleolus-like inclusions in the cytoplasm of HeLa cells treated with puromycin. *Nature*, 203:883-884, 1964.
9. Love R, **Studzinski GP**, Clark AM and Tressan ER: Studies on the cytochemistry of nucleoproteins. IV. Characterization of a granular form of ribonucleoprotein in the cytoplasm. *J Nat Cancer Inst*, 35:55-66, 1965.
10. **Studzinski GP**: Selective binding of zinc by basic proteins of the HeLa cell nucleolus. *J Histochem Cytochem*, 13:365-375, 1965.
11. **Studzinski GP** and Jackson LG: Inhibition by puromycin of the incorporation of tritiated uridine into nucleolar and cytoplasmic RNA. *Nature*, 212:194-196, 1966.
12. **Studzinski GP** and Baserga R: Instability of puromycin. *Nature*, 212:196-197, 1966.
13. **Studzinski GP** and Ellem KAO: Relationship between RNA synthesis, cell division and morphology of mammalian cells. I. Puromycin aminonucleoside as an inhibitor of RNA synthesis and division in HeLa cells. *J Cell Biol*, 29:411-421, 1966.
14. **Studzinski GP** and Cohen LS: Mitomycin C induced increases in the activities of the deoxyribonucleases of HeLa cells. *Biochem Biophys Res Comm*, 23:506-512 1966.
15. Clark AM, Love R, **Studzinski GP** and Ellem KAO: A correlated morphological and functional study of the effects of actinomycin D on HeLa cells. I. Effects on the nucleolar and cytoplasmic ribonucleoproteins. *Exp Cell Res*, 45:106-119, 1966.
16. **Studzinski GP**, Cohen LS, Roseman J and Schweitzer JL: Elevation of deoxyribonuclease activities in HeLa cells treated with selective inhibitors on DNA synthesis. *Biochem Biophys Res Comm* 25:313-319, 1966.
17. Cohen LS and **Studzinski GP**: Correlation between cell enlargement and nucleic acid and protein content of HeLa cells in unbalanced growth produced by inhibitors of DNA synthesis. *J Cell Physiol* 69:331-319, 1967.
18. **Studzinski GP**, Reidbord HE and Love R: Enhancement of the affinity of nucleoli and chromosomes for zinc by treatment with chromatic acid. *Stain Technology*, 42: 301-306, 1967.

19. Lambert WC and **Studzinski GP**: Recovery from prolonged unbalanced growth induced in HeLa cells by high concentration of thymidine. *Cancer Res*, 27:2364-2369, 1967.
20. **Studzinski GP**, Jackson LG and Perry RP: Contributions of aminoacyl transfer RNA to protein label in autoradiographic experiments. *J Histochem Cytochem*, 15:702, 1967.
21. Jackson LG and **Studzinski GP**: Autoradiographic studies of the effects of inhibitors of protein synthesis on RNA synthesis in HeLa cells. *Exp Cell Res*, 52:408-418, 1967.
22. **Studzinski GP** and Ellem KAO: Differences between diploid and heteroploid cultured mammalian cells in their response to puromycin aminonucleoside. *Cancer Res* 28:1773-1782, 1968.
23. **Studzinski GP** and Lambert WC: Fallacies in the introduction of synchrony in HeLa cell cultures by inhibitors of DNA synthesis. *In Vitro* 4:139-140, 1968.
24. **Studzinski GP** and Lambert WC: Thymidine as a synchronizing agent. I. Nucleic acid and protein formation in synchronous HeLa cultures treated with excess thymidine. *J Cell Physiol* 73:109-117, 1969.
25. Lambert WC and **Studzinski GP**: Thymidine as a synchronizing agent. II. Partial recovery of HeLa cells from unbalanced growth. *J Cell Physiol* 73:261-266, 1969.
26. Love R and **Studzinski GP**, Walsh RJ: Nuclear, Nucleolar and cytoplasmic acid phosphates in cultured mammalian cells. *Exp Cell Res* 58:62-72, 1969.
27. Churchill JR and **Studzinski GP**: Thymidine as a synchronizing agent. III. Persistence of cell cycle patterns of phosphatase activities and elevation of nuclease activity during inhibition of DNA synthesis. *J Cell Physiol* 75:297-304, 1970.
28. **Studzinski GP** and Gierthy JF: Cytologic appearance of the nucleolus of normal and neoplastic cells in relation to the synthesis of RNA. *Acta Cytol* 16:245-248, 1972.
29. **Studzinski GP** and Gierthy JF: Selective inhibition of the cell cycle of cultured human diploid fibroblasts by aminonucleoside of puromycin. *J Cell Physiol* 81:71-83, 1973.
30. **Studzinski GP**, Gierthy JF and Cholon JJ: An autoradiographic screening test for mycoplasmal contamination of mammalian cell cultures. *In Vitro* 8:466-472, 1973.
31. Churchill JR, Urbanczyk J and **Studzinski GP**: Multiple deoxyribonuclease activities in nuclei of HeLa cells. *Biochem Biophys Res Comm* 53:109-1016, 1973.
32. Gierthy JF and **Studzinski GP**: Absence of aminonucleoside-sensitive steps in the cell cycle of SV4-transformed human fibroblasts. *Cancer Res* 33:2673-2676, 1973.

33. **Studzinski GP** and Fischman GJ: Activation of DNA primer for DNA polymerase and an ultra sensitive assay for deoxyribonuclease activity. *Anal Biochem* 58:449-458, 1974.
34. Cholon JJ and **Studzinski GP**: Effect of aminonucleoside on serum stimulation on non-histone nuclear proteins and DNA synthesis in normal and SV40-transformed human fibroblasts. *Cancer Res* 34:588-593, 1974.
35. **Studzinski GP**: Molecular basis of cell proliferation: the cell cycle. *Ann Clin Lab Sci* 4:115-120, 1974.
36. Cholon JJ and **Studzinski GP**: Metabolic differences between normal and neoplastic cells: effects of aminonucleoside on cytoplasmic messenger RNA. *Science* 184:160-161, 1974.
37. Urbanczyk J and **Studzinski GP**: Chromatin-associated DNA endonuclease activities in Hela cells. *Biochem Biophys Res Comm* 59:616-622, 1974.
38. Chirife AM and **Studzinski GP**: Definition of the cell cycle segment with special sensitivity to vinblastine. *Proc Soc Exp Biol Med* 157:206-210, 1978.
39. Fischman GJ, Lambert MW and **Studzinski GP**: Purification and properties of a nuclear DNA endonuclease from Hela cells. *Biochem Biophys Acta* 567:464-471, 1979.
40. Albanese EA and **Studzinski GP**: Selective inhibition of preribosomal RNA synthesis by puromycin aminonucleoside in transformed human fibroblasts: studies of the nature of the inhibition in isolated nuclei and nucleoli. *J Cell Physiol* 99:55-66, 1979.
41. Albanese EA and **Studzinski GP**: Metabolism of puromycin aminonucleoside in transformed human lung fibroblasts and the mechanism of its inhibition of RNA synthesis. *Molec Pharmacol* 17:262-267, 1980.
42. Lambert MW and **Studzinski GP**: DNA endonuclease activities associated with melanoma cell chromatin. *Biochem Biophys Res Comm* 91:1481-1487, 1980.
43. **Studzinski GP** and Albanese EA: Nascent RNA chain termination and ultrastructural changes in nucleoli isolated from SV40-transformed fibroblasts treated with aminonucleoside of puromycin. *Lab Invest* 43:427-433, 1980.
44. **Studzinski GP**, Albanese EA, Scatina J and Simchera J: Fibroblasts transformed by an oncogenic virus show decreased uptake of puromycin aminonucleoside. *Biochem Biophys Res Commun* 95:1446-1451, 1980.
45. Albanese EA and **Studzinski GP**: Uptake of puromycin aminonucleoside in relation to the inhibition of nucleic acid synthesis in normal and transformed human lung fibroblasts. *In Vitro* 16:220, 1980
46. Tunkel AR and **Studzinski GP**: Effect of aminonucleoside on transcription, methylation, and maturation of ribosomal RNA in SV40-transformed human lung fibroblasts. *J Cell Physiol* 108:239-249, 1981.

47. Fox N, Fernandez C and **Studzinski GP**: Visualization of nucleolar structure in cultured human fibroblasts by magnesium-activated adenosine triphosphatase reaction. *J Histochem Cytochem* 29:1114-1120, 1981.
48. Fox N and **Studzinski GP**: DNA dependence and inhibition by novobiocin and coumermycin of the nucleolar ATPase of human fibroblasts. *J Histochem Cytochem* 30:364-370, 1982.
49. Albanese EA and **Studzinski GP**: Basis for the differential action of aminonucleoside on normal and transformed human fibroblasts. *J Natl Cancer Inst* 68:407-413, 1982.
50. Chung H, Albanese EA and **Studzinski GP**: Differential effect of cofomycin on the cell cycle traverse of normal and SV40-transformed human fibroblasts. *Cancer Res* 43:1269-1274, 1983.
51. **Studzinski GP**, Brelvi ZS and Fernandez C: Comparison of nucleolar DNA-topoisomerase 2 activity in Franconi anemia and other chromosome breakage syndromes. *Normal and Neoplastic Hematopoiesis. UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 9*, eds. David W. Golde and Paul A. Marks. Alan R. Liss, Inc., New York, NY, 417-424, 1983.
52. Tunkel AR and **Studzinski GP**: Adenosine analogues induce ultrastructural changes in the nucleolus which correlate with inhibition of ribosomal RNA processing. *J Histochem Cytochem* 32:363-371, 1984.
53. Wake EJ and **Studzinski GP**: Degenerative changes in human cultured cells exposed to a perfluorochemical blood substitute fluosol - DA. *Transfusion* 25:73-77, 1985.
54. **Studzinski GP**, Bhandal AK and Brelvi ZS: A system for monocytic differentiation of leukemic cells HL 60 by 1,25-dihydroxycholecalciferol. *Proc Soc Exp Biol Med* 179:288-295, 1985.
55. **Studzinski GP**, Bhandal AK and Brelvi ZS: Cell cycle sensitivity of HL 60 cells to the differentiation-inducing effects of 1-alpha,25-dihydroxyvitamin D₃. *Cancer Res* 45:3898-3905, 1985.
56. **Studzinski GP**, Bhandal AK and Brelvi ZS: Potentiation by 1-alpha,25-dihydroxyvitamin D₃ of cytotoxicity to HL 60 cells produced by cytarabine and hydroxyurea. *J Natl Cancer Inst*, 76:641-648, 1986.
57. Brelvi ZS and **Studzinski GP**: Changes in the expression of oncogenes encoding nuclear phosphoproteins but not c-Ha-ras have a relationship to monocytic differentiation of HL 60 cells. *J Cell Biol*, 102:2234-22, 1986.
58. Brelvi ZS and **Studzinski GP**: Inhibition of DNA synthesis by an inducer of differentiation of leukemic cells, 1, alpha, 25 dihydroxyvitamin D₃ precedes down regulation of the c-myc gene. *J Cell Physiol*, 128:171-179, 1986.
59. Brelvi ZS, Christakos S and **Studzinski GP**: Expression of monocyte-specific oncogenes c-fos and c-fms in HL 60 cells treated with vitamin D₃ analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. *Lab Invest*, 55:269-275, 1986.
60. **Studzinski GP**, Brelvi ZS, Feldman SC and Watt RA: Participation of c-myc protein in DNA synthesis of human cells. *Science*, 234:457-470, 1986.

61. **Studzinski GP** and Brelvi ZS: Changes in proto-oncogene expression associated with reversal of macrophage-like differentiation of HL 60 cells. *J Natl Cancer Inst*, 79:67-76, 1987.
62. Watt RA and **Studzinski GP**, Sullivan NF: Functional characterization of the myc protein. *Current Comm in Molec Biology (Cold Spring Harbor)* 25:1-6, 1987.
63. Brelvi ZS and **Studzinski GP**: Coordinate expression of c-myc, c-myb and histone H4 genes in reversibly differentiating HL 60 cells. *J Cell Physiol*, 131:43-49, 1987.
64. Studzinski GP and Brelvi ZS: Increased expression of oncogene c-Ha-ras during granulocytic differentiation of HL 60 cells. *Lab Invest*, 56:499-504, 1987.
65. **Studzinski GP** and Brelvi ZS: Patterns of proto-oncogene expression associated with varying potentials for cell proliferation. *Cell Tissue Kinet* 21:51, 1988.
66. Matthew PA, Ellis LK and **Studzinski GP**: Expression of differentiation-related proto-oncogenes is spared during partial inhibition of RNA synthesis. *Cell Tissue Kinet* 21:63, 1988.
67. Matthew PA, Ellis LK and **Studzinski GP**: Enhanced messenger RNA stability and differentiation of HL 60 cells treated with 1,25-dihydroxyvitamin D₃ and cordycepin. *J. Cell Physiol*, 140:212-218, 1989.
68. Satav JG, Mukund J, Modak and **Studzinski GP**: Photoaffinity labeling of human c-myc protein with dTTP. *Lab Investigation*, 63:551-556, 1990.
69. Moore DC, Carter DL, Bhandal AK, Li M and **Studzinski GP**: Inhibition by 1,25 dihydroxyvitamin D₃ of chemically induced erythroid differentiation of K562 leukemia cells. *Blood*, 77:1452-1461, 1991.
70. **Studzinski GP**, Shankavaram UT, Moore DC and Reddy PV: Association of c-myc protein with enzymes of DNA replication in high molecular weight fractions from mammalian cells. *J. Cell Physiol*. 147:412-419, 1991.
71. Kolla SS, Moore DC and **Studzinski GP**: Vitamin D analogs inhibit erythroid differentiation and induce monocytic differentiation of leukemic cells with the same relative potency. *Proc. Soc. Expl. Biol. & Med.*, 197:214-217, 1991.
72. Pan P, Reddy K, Lee S and **Studzinski GP**: Differentiation-related regulation of 1,25-dihydroxyvitamin D₃ receptor mRNA in human leukaemia cells HL-60. *Cell Prolif.* 24:159-170, 1991.
73. **Studzinski GP**, Reddy KB, Hill HZ and Bhandal AK: Potentiation of ara-c cytotoxicity to HL60 cells by 1,25(OH)₂ vitamin D₃ correlates with a reduced rate of maturation of DNA replication intermediates. *Cancer Research*; 51:3451-3455, 1991.
74. Moore DC, Carter DL and **Studzinski GP**: Inhibition by 1,25 dihydroxyvitamin D₃ of c-myc down-regulation and DNA fragmentation in cytosine arabinoside-induced erythroid differentiation of K562 cells. *J. Cell Physiol*, 151:539-548, 1992.
75. Tepper CD, Pater MM, Pater A, Xu HM and **Studzinski, GP**: Mitochondrial nucleic acids as internal standards for blot hybridization studies. *Analytical Biochem.* 203:127-133, 1992.

76. Tepper CG, **Studzinski GP**: Teniposide induces nuclear not mitochondrial DNA degradation. *Cancer Research*, 52:3384-3390, 1992.
77. Xu HM, Kolla SS, Goldenberg NA and **Studzinski GP**: Resistance to 1,25-dihydroxyvitamin D₃ of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. *Experimental Cell Research*, 203:244-250, 1992.
78. Kolla SS, **Studzinski, GP**: Resolution of multiple AP-1 complexes in HL-60 cells induced to differentiate by 1,25-dihydroxyvitamin D₃. *J. Cell Physiol*, 156:63-71, 1993.
79. Tepper CG, **Studzinski, GP**: Resistance of mitochondrial DNA to degradation characterizes the apoptotic but not the necrotic mode of human leukemia cell death. *Journal of Cellular Biochemistry*, 52:352-361, 1993.
80. Xu HM, Tepper, CG, Jones, JB Fernandez CE and **Studzinski, GP**: 1,25-dihydroxyvitamin D₃ protects HL60 cells against apoptosis but down-regulates the expression of bcl-2 gene. *Exp. Cell Res.*, 209:367-374, 1993.
81. Godyn JJ, Xu HM, Zhang F, Kolla SS, and **Studzinski GP**: A dual block to cell cycle progression in HL60 cells exposed to analogs of vitamin D₃. *Cell Prolif*, 27:37-46, 1994.
82. Kolla SS, and **Studzinski GP**: Constitutive DNA binding of the low mobility forms of the AP-1 and SP-1 transcription factors in HL60 cells resistant to arabinocytosine. *Cancer Res*, 54:1418-1421, 1994.
83. Kolla, SS, Xu, HM and **Studzinski, GP**: Disparate regulation of c-fos and c-jun genes in differentiation sensitive and resistant HL-60 cells exposed to 1,25(OH)₂ vitamin D₃. *Molecular & Cellular Differentiation*, 2:169-184, 1994.
84. Zhang, F, Godyn, JJ, Uskokovic, M, Binderup, L, and **Studzinski, GP**: Monocytic differentiation of HL60 cells induced by potent analogs of vitamin D₃ precedes the G1/G0 phase cell cycle block. *Cell Prolif*, 27:643-654, 1994.
85. **Studzinski, GP** and Moore, GD: Sunlight - Can it prevent as well as cause cancer? *Cancer Research*, 55:4011-4022, 1995.
86. Wang, QM, Jones, JB and **Studzinski, GP**: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1/S phase block induced by 1,25-dihydroxyvitamin D₃ in HL60 cells. *Cancer Research*, 56:264-267, 1996.
87. Zhang, F, Rathod, B, Jones, JB, Wang, QM, Bernhard, E, Godyn, JJ and **Studzinski, GP**: Increased stringency of the 1,25-dihydroxyvitamin D₃-induced G1 to S phase block in polyploid HL60 cells. *J. Cell Physiol*, 168:18-25, 1996.
88. Wajchman, HJ, Rathod, B, Song, S, Xu, H, Wang, X, Uskokovic, MR, and **Studzinski, GP**: Loss of deoxycytidine kinase expression and tetraploidization of HL60 cells following long-term culture in 1,25-dihydroxyvitamin D₃. *Exp. Cell Res.* 224:312-322, 1996.

89. **Studzinski, GP**, Rathod, B, Rao, J, Kheir, A, Wajchman, HJ, Zhang, F, Finan, FB, and Nowell, PC: Transition to tetraploidy in 1,25-(OH)₂-vitamin D₃ resistant HL60 cells is preceded by reduced growth factor dependence and constitutive up-regulation of Sp1 and AP-1 transcription factors. *Cancer Research*, 56:5513-5521, 1996.
90. Gardner, JP, Zhang, F, Uskokovic, MR, and **Studzinski, GP**: Vitamin D analog 25-(OH)-16-,23E-diene-26,27-hexafluoro-vitamin D₃ induces differentiation of HL60 cells with minimal effects on the cellular calcium homeostasis. *J. Cell Biochem.*, 63:500-512, 1996.
91. **Studzinski, GP**, Rathod, B, Wang, QM, Rao, J. and Zhang, F: Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. *Exp. Cell Res.*, 323:376-387, 1997.
92. Gardner, JP, Balasubramanyam, M. and **Studzinski, GP**: Up-regulation of Ca²⁺ influx mediated by store-operated channels in HL60 cells induced to differentiate by 1α,25-dihydroxyvitamin D₃. *J. Cellular Physiol*, 172:284-295, 1997.
93. Wang, X, Ponzio, NM, **Studzinski, GP**: Long-term exposure of HL60 cells to 1,25-dihydroxyvitamin D₃ reduces their tumorigenicity: A model for cancer chemoprevention. *Proc. Soc Exp Biol. Med*, 215:399-404, 1997.
94. Wang, X, Gardner, JP, Kheir, A, Uskokovic, MR, and **Studzinski, GP**: Synergistic induction of HL60 cell differentiation by ketoconazole and 1-desoxy analogs of vitamin D₃ with minimal effects on intracellular calcium. *J. Natl. Cancer Inst.*, 89:1199-1206, 1997.
95. Wang, QM, Luo, X, and **Studzinski, GP**: Cyclin-dependent kinase 6 is the principal target of p27/Kip1 - regulation of the G1 phase traverse in 1,25-dihydroxyvitamin D₃-treated HL60 cells. *Cancer Research*, 57:2851-2855, 1997.
96. Wang, X, and **Studzinski, GP**: Anti-apoptotic action of 1,25-dihydroxyvitamin D₃ is associated with increased mitochondrial Mcl-1 and Raf-1 proteins and reduced release of cytochrome c. *Exp. Cell Res.*, 235:210-217, 1997.
97. Reichman, TW, Albanell, J, Wang, X, Moore, MAS, **Studzinski, GP**: Down-regulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. *J. Cellular Biochem*, 67:13-23, 1997.
98. Uskokovic, MR, **Studzinski, GP**, Gardner, JP, Reddy, SG, Campbell, MJ, and Koeffler, PH: The 16-ene vitamin D analogs. *Current Pharmaceutical Design*, 3:99-123, 1997.
99. Rao, J, Zhang, F, Donnelly, R, Spector, NL, and **Studzinski, GP**: Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL60 cells. *J. Cellular Physiol.*, 175:121-128, 1998.
100. Wang, QM, Luo, X, Kheir, A, Coffman, FD, and **Studzinski, GP**: Retinoblastoma protein- overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D₃ display increased CDK2 and CDK6 activity and shortened G1 phase. *Oncogene*, 16:2729-2737, 1998.

101. Wang, QM, Chen, F, Luo, X, Moore, DC, Flanagan, M, and **Studzinski, GP**: Lowering of p27kip1 levels by its antisense oligonucleotide or by development of resistance to 1,25-dihydroxyvitamin D₃ reverses the G1 block but not differentiation of HL60 cells. *Leukemia*, 12:1256-1265, 1998.
102. Chen, F, and **Studzinski, GP**: Cyclin-dependent kinase 5 activity enhances monocytic phenotype and cell cycle traverse in 1,25-dihydroxyvitamin D₃- treated HL60 cells. *Exp Cell Res*, 249:422-428, 1999.
103. Harrison, LE, Wang, QM, and **Studzinski, GP**: 1,25-dihydroxyvitamin D₃-induced retardation of the 2/M traverse is associated with decreased levels of p34cdc2 in HL60 cells. *J. Cellular Biochem.*, 75:226-231, 1999.
104. Harrison, LE, Wang, QM, and **Studzinski, GP**: Butyrate-induced G2 block in CaCo-2 colon cancer cells is associated with decreased p34cdc2 activity. *Proc. Soc. Exper. Biol Med*, 222:150-156, 1999.
105. Chen, F, Rao, J, and **Studzinski, GP**: Specific association of increased cyclin-dependent kinase 5 expression with monocytic lineage of differentiation of human leukemia HL60 cells. *J. Leukocyte Biol*, 67:559-556, 2000.
106. Wang, QM, **Studzinski, GP**, Chen, F, Coffman, FD, and Harrison, LE: p53/56lyn antisense shifts the 1,25 dihydroxyvitamin D₃-induced G1/S block in HL60 cells to S phase. *J. Cell Physiol*, 183:238-246, 2000.
107. Chen, F, Zhang, F, Rao, J, **Studzinski, GP**: Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. *Anticancer Research*, 20:661-668, 2000.
108. Wang, QM, Feinman, R, Kashanchi, F, Houghton, J, **Studzinski, GP**, Harrison, LE: Changes in E2F binding after phenylbutyrate induced differentiation of CaCo2 colon cancer cells. *Clinical Cancer Res.*, 6:2951-2958, 2000.
109. Wang, X, Rao, J, **Studzinski, GP**: Inhibition of p38 MAP kinase activity upregulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D₃-induced differentiation of human leukemia HL60 cells. *Exp Cell Research*, 258:425-437, 2000.
110. Wang, X, **Studzinski, GP**: Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25 dihydroxyvitamin D₃-induced differentiation of HL60 cells. *J. Cellular Biochem*, 80:471-482, 2001.
111. Uskokovic MR, Norman AW, Manchand PS, **Studzinski, GP**, Campbell MJ, Koeffler HP, Takeuchi A, Siu-Caldera M, Rao DS, Reddy GS: Highly active analogs of 1alpha,25-dihydroxyvitamin D₃ that resist metabolism through C-24 oxidation and C-3 epimerization pathways. *Steroids*, 66:463-471, 2001.
112. Chen, F, **Studzinski, GP**: Expression of the neuronal cyclin-dependent kinase 5 activator p35Nck5a in human monocytic cells is associated with differentiation. *Blood*, 97:3763-3767, 2001.
113. Wang, X, **Studzinski, GP**: Inhibition of p38 MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. *J. Cellular Biochem.*, 82:68-77, 2001.

114. Wang, X **Studzinski, GP**: Phosphorylation of Raf-1 by Kinase Suppressor of Ras (KSR-1) is inhibited by “MEK-Specific” inhibitors PD098059 and U0126 in differentiating HL60 cells. *Exp. Cell Res.* 268:294-300, 2001.
115. Danilenko, M, Wang, X , **Studzinski, GP**: Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. *J. Natl Cancer Inst*, 93:1224-1233, 2001.
116. Ji, Y, Wang, X, Donnelly, RJ, Uskokovic, MR, **Studzinski, GP**: Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D₃, 1,25(OH)₂-5,6 trans-16-ene-vitamin D₃, involves nuclear vitamin D receptor (nVDR) & non nVDR-mediated pathways. *J.Cell.Physiol.*, 191:198-207, 2002.
117. Ji, Y, Kutner, A, Verstuyf, M, Verlinden, L, **Studzinski, GP**: Derivatives of vitamins D₂ and D₃ activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. *Cell Cycle*, 1:410-415 2002.
118. **Studzinski, PG**, Harrison, JS.: The neuronal cyclin-dependent kinase 5 activator p35Nck5a and Cdk5 activity in monocytic cells. *Leukemia and Lymphoma*, 44:235-240, 2003.
119. Danilenko, M, Wang, Q, Wang, X, Levy, J, Sharoni, Y, **Studzinski, GP**: Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1 α ,25-dihydroxyvitamin D₃ in leukemia cells, but does not promote elevation of basal levels of intracellular calcium. *Cancer Res.* 63:1325-1332, 2003.
120. Wang, Q, Wang, X, **Studzinski, G**: The jun N-terminal kinase pathway participates in signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D₃. *J. Cellular Biochem.* 89:1087-1101, 2003.
121. Wang, X. and **Studzinski GP**: Kinase suppressor of RAS (KSR) amplifies the differentiation signal provided by low concentrations 1,25Dihydroxyvitamin D₃. *J. Cellular Physiology*, 198:333-342, 2004.
122. Weyts, FA, Dhawan, P, Zhang, X, Bishop, JE, Uskokovic, MR, Ji, Y, **Studzinski, GP**, Norman, AW and Christakos, S: Novel gemini analogs of 1 α ,25-dihydroxyvitamin D₃ with enhanced transcriptional activity. *Biochem Pharmacology*, 67:1327-1336, 2004.
123. Demidenko, ZN, **Studzinski, GP**, Blagosklomy, MV: From cytometry to cell cycle: a portrait of Zbigniew Darzynkiewicz. *Cell Cycle*, 3:525-528, 2004.
124. Ji, Y. and **Studzinski, GP**: Retinoblastoma protein and CCAAT/Enhancer-binding protein β are required for 1,25-dihydroxyvitamin D₃-induced monocytic differentiation of HL60 cells. *Cancer Res.* 64:370-377, 2004.
125. Chen, F, Wang, Q, Wang, X, **Studzinski, GP**: Up-regulation of Egr1 by 1,25-dihydroxyvitamin D₃ contributes to increased expression of p35 activator of cyclin-dependent kinase and consequent onset of the terminal phase of HL60 cell differentiation. *Cancer Research*, 64:5425-5433, 2004.
126. Wang, Q, Salman, H, Danilenko, M, **Studzinski, P**: Cooperation between antioxidants and 1,25-dihydroxyvitamin D₃ in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. *J Cell Physiol*, 204:964-974, 2005.

127. **Studzinski, GP**, Wang, X, Yan, J, Wang, Q, Yingyu, Z, Kutner, A, Harrison, JS: The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. *J Steroid Biochem & Mol. Biol*, 97:47-55, 2005.
128. Wang, Q, Harrison, JS, Uskokovic, M, Kutner, A, **Studzinski, GP**: Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination of p38 MAPK inhibitor and an antioxidant. *Leukemia*, 19:1812-1817, 2005.
129. Zhang, Y, Zhang, J, **Studzinski, GP**: AKT pathway is activated by 1,25-dihydroxyvitamin D₃ and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. *Cell Cycle* 5:447-451, 2006.
130. Sharabani, H, Izumchenko, E, Wang, Q, Kreinin, R, Steiner, M, Barvish, Z, Kafka, M, Sharoni, Y, Levy, J, Uskokovic, M, **Studzinski, GP**, Danilenko, M: Comparative antitumor effects of vitamin D₃ derivatives and rosemary preparations in a mouse model of myeloid leukemia. *J. Internat Cancer*, 118:3012-3021, 2006.
131. Marcinkowska, E, Garay, E, Gocek, E, Chrobak, A, Wang, X, **Studzinski, GP**: Regulation of C/EBP β isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D₃. *Experimental Cell Research*, 312:2054-2065, 2006.
132. Wang, X, **Studzinski, GP**: The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D₃. *Cancer Res.* 66:4402-4409, 2006.
133. Wang, X, Wang, T-T, White, JH, **Studzinski, GP**: Induction of Kinase Suppressor of RAS-1 (KSR-1) gene by 1,25-dihydroxyvitamin D₃ in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region. *Oncogene*, 25:7078-85, 2006.
134. Wang, X, **Studzinski GP**: Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D₃-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module. *J Cell Physiol*, 209:253-260, 2006.
135. **Studzinski, GP**, Garay, E, Patel, R, Zhang, J, Wang, X: Vitamin D receptor signaling of monocytic differentiation in human leukemia cells; role of MAPK pathways in transcription factor activation. *Medicinal Chemistry*, 6:1267-1271, 2006.
136. Zhang, J, Posner, GH, Danilenko, M, **Studzinski, GP**: Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combinations with an antioxidant and a p38 MAPK inhibitor which upregulates the JNK pathway. *J Steroid Biochem Mol Biol*, 105:140-149, 2007.
137. Garay, E, Jankowski, P, Lizano, P, Marczak, S, Jankowski, P, Maehr, H, Adorini, L, Uskokovic MR, **Studzinski, GP**: Calcitriol derivatives with two different side-chains at C-20. Further chain modifications that alter VDR-dependent monocytic differentiation potency in human leukemia cells, *Bioorganic Med Chem*, 15:4444-55, 2007.
138. Wang, X, Wang, T-T, White, JH, **Studzinski, GP**: Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D₃ and is required for optimal cell differentiation. *Experimental Cell Research*, 313:3034-3045, 2007. PMID 17599837

139. Garay, E, Donnelly, R, Wang, X, **Studzinski, GP**: Resistance to 1,25D-induced differentiation in human acute myeloid leukemia HL60-40AF cells is associated with reduced transcriptional activity and nuclear localization of the vitamin D receptor. *J Cell Physiol*, 213:816-825, 2007.
140. Jamshidi, F, Zhang, J, Harrison, JS, Wang, X, **Studzinski, GP**: Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D₃ involves Raf1 but not Erk 1/2 signaling. *Cell Cycle*, 7: 917-924, 2008. PMID 18414055
141. Shabtay, A, Sharabani, H, Barvish Z, Kafka, M, Amichay, D, Levy, J, Sharoni, Y, Uskokovic MR, **Studzinski, GP**, and Danilenko, M: Synergistic Antileukemic activity of carnosic acid-rich rosemary extract and 19-nor Gemini vitamin D analog in a mouse model of systemic acute myeloid leukemia. *Oncology*, 75(3-4): 203-214, 2008. PMID 18852491
142. Wang, X, Patel, R, and **Studzinski GP**: hKSR-2, a Vitamin D-regulated gene, inhibits apoptosis in AraC-treated HL60 leukemia cells. *Molecular Cancer Therapeutics*, 7:2799-2506, 2008. PMID 18790760.
143. Wang X, Gocek, E, Liu CG, **Studzinski, GP**: MicroRNAs181 regulate the expression of p27(Kip1) in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D₃. *Cell Cycle*. 1;8(5):736-41. PMID: 19221487. Epub Mar 18,2009
144. Chen-Deutsch, X, Garay, E, Zhang, J, Harrison, JS and **Studzinski, GP**: Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D, *Leukemia Research*, 33(10): 1372-8, 2009. PMID: 19339050.
145. Zhang, J, Harrison, JS, Uskokovic, M, Danilenko, M and **Studzinski, GP**: Silibinin can induce differentiation as well as enhance vitamin D₃-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. *Hematological Oncology*, 28(3): 124-32, Sep. 2010. PMID: 19866452.
146. Pesakhov S, Khanin M, Danilenko, M, **Studzinski, GP**: Distinct combinational effects of the plant polyphenoids curcumin, carnosic acid and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. *Nutrition & Cancer*, 62(6):811-24, 2010. PMID: 20661831
147. Wang, X and **Studzinski, GP**: Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D₃ in parallel with activated c-jun during differentiation of human myeloid leukemia cell. *J. Steroid Biochem. & Mol. Biol.* 121(1-2):395-8, Jul. 2010. PMID: 20227498.
148. Thompson T, Andreeff M, **Studzinski, GP**, Vassilev LT: 1,25-Dihydroxyvitamin D₃ enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. *Mol Cancer Ther.* 9(5):1158-68, May 2010. PMID 20406950.
149. Thompson T, Vassilev LT, Danilenko M and **Studzinski, GP**: Tumor suppressor p53 status does not determine the differentiation-associated G1 cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D and antioxidants. *Cancer Biology & Therapy*, 10(4): 344-50. PMID:20543580, Aug. 2010.
150. Wang X, Gocek E, Novik V, Harrison JS, Danilenko M, **Studzinski GP**: Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with

enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D₃. *Cell Cycle* 9(22): 4542-51, Nov. 15, 2010. PMID: 21084834.

151. Wang X, Gocek E, Novik V, Harrison JS, Danilenko M, **Studzinski GP**: Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D₃. *Cell Cycle*, 9(22):4542-51. Dec. 7, 2010. Epub Nov 15, 2010.

152. Wang X, Gocek E, Novik V, Harrison JS, Danilenko M, **Studzinski GP**: Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D₃. *Cell Cycle*, 9(22):4542-51. Dec. 7, 2010. Epub Nov 15, 2010.

153. Wang X, **Studzinski, GP**: Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D₃-induced differentiation of human acute myeloid leukemia cells. *J Cell Physiol* 226(5):1232-40. May 2011.

154. Zhang J, Harrison JS, **Studzinski GP**: Isoforms of p38 MAPK gamma and delta contribute to differentiation of human AML cells induced by 1, 25-dihydroxyvitamin D₃. *Exp Cell Res*, 317(1):117-30, Jan 1, 2011. PMID: 20804750.

155. Gocek E, Wang X, Liu X, Liu CG, **Studzinski, GP**: MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D₃ in human myeloid leukemia cells lead to Bim targeting and inhibition of AraC-induced apoptosis. *Cancer Res*. Aug. 4. 2011. PMID: 21816906.

156. Bobilev I, Novik V, Levi I, Shpilberg O, Levy J, Sharoni Y, **Studzinski GP**, Danilenko M: The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells. *Cancer Biol Ther*, 11(3) 317-29, Feb. 2011. PMID: 21099366.

157. Chen-Deutsch X and **Studzinski.GP**: Dual role of Hematopoietic Progenitor Kinase 1 (HPK1) as a positive regulator of 1 α ,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and a mediator of vitamin D resistance. *Cell Cycle* 11(7):1364-73, Apr. 1, 2012. PMID: 22421156.

158. Chen-Deutsch X, Kutner A, Harrison JS, **Studzinski, GP**: The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells. *Leuk Res*. 36(7):884-8, July 2012. PMID: 22541691.

159. Halicka HD, Zhao H, Li J, Traganos F, **Studzinski GP**, Darzynkiewicz Z: Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D₃. *Aging (Albany NY)*.. (4):270-8, 2012. PMID: 22498490.

160. Duggal J., Harrison JS, **Studzinski GP**, Wang X: Involvement of MicroRNA181a in Differentiation and Cell Cycle Arrest Induced by a Plant-derived Antioxidant Carnosic Acid and Vitamin D Analog Doxerciferol in Human Leukemia Cells. *MicroRNA*, 1, 26-33, 2012. PMID: 25048087.

161. Wang X, Pesakhov, S, Harrison JS, Danilenko, M and **Studzinski, GP**: ERK5 pathway regulates transcription factors important for monocytic differentiation of human Myeloid Leukemia cells. *J Cell Physiol*. 2014; 229:856-67, 2014. PMID: 24264602.

162. Wang X, Pesakhov S, Weng AF, Gocek E, Nguyen M, Harrison JS, Danilenko M and **Studzinski GP**. ERK 5/MAPK pathway has a major role in $1\alpha,25\text{-(OH)}_2$ vitamin D₃-induced terminal differentiation of myeloid leukemia cells. *J Steroid Biochem Mol Biol*. 144 Pt A: 223-7, 2014. PMID: 24514755.
163. Yuzefpolskiy Y, Baumann FM, Penny LA, **Studzinski GP**, Kalia V, Sarkar S: Vitamin D receptor signals regulate effector and memory CD8 T cell responses to infections in mice. *J Nutr*. 144: 2073-82, 2014. PMID: 25320188.
164. Wang X, Pesakhov S, Harrison JS, Kafka M, Danilenko M, **Studzinski GP**: The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage. *Exp Cell Res*. 330: 199-211, 2015. PMID: 25447310.
165. Zheng R, Wang X, **Studzinski GP**: 1,25-Dihydroxyvitamin D₃ induces monocytic differentiation of human myeloid leukemia cells by regulating C/EBP β expression through MEF2C. *J Steroid Biochem Mol Biol*. 148:132-7, 2015. PMID: 25448741.
166. **Studzinski GP**, Harrison JS, Wang X, Sarkar S, Kalia V, Danilenko M: Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia. *J Cell Biochem*. 116:1500-12, 2015. PMID: 25694395.
167. Wang X, Harrison JS, **Studzinski GP**: Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination. *J Steroid Biochem Mol Biol*. pii: S0960-0760, 30055-8., 2015. PMID: 26319201.
168. Pesakhov S, Nachliely M, Barvish Z, Aqaq N, Schwartzman B, Voronov E, Sharoni Y, **Studzinski GP**, Fishman D, Danilenko M: Cancer-selective cytotoxic Ca²⁺ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid. *Oncotarget*. 7: 31847-61, 2016. PMID: 26870993.
169. Harrison JS, Wang X, **Studzinski GP**: The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts. *Oncotarget*. Epub ahead of print, 2016. PMID: 27144333.
170. Wang X, Harrison JS, **Studzinski GP**. BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents. *J Steroid Biochem Mol Biol*. Epub ahead of print, 2016. PMID: 27637326.
171. Zheng R, Studzinski GP. Nuclear ERK5 inhibits progression of leukemic monocytes to macrophages by regulating expression of the transcription factor PU.1 and heat shock protein HSP70. *Leukemia & Lymphoma*. 2017 Jun;58(6):1468-1480. doi: 10.1080/10428194.2016.1243675. Epub 2016 Oct 17. PMID: 27748139.
172. Zheng R, Studzinski GP. Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity. *J Cell Biochem*. 2017 Jun;118 (6):1583-1589. doi: 10.1002/jcb.25820. Epub 2017 Jan 11. PMID: 27922189.
173. Wang X, Beute WK, Harrison JS, Studzinski GP. JNK1 as a signaling node in VDR-BRAF induction of cell death in AML. *J Steroid Biochem Mol Biol*. 2018 Mar;177:149-154. doi: 10.1016/j.jsbmb.2017.07.005. PMID: 28765039.
174. Wang X, Nachliely M, Harrison JS, Danilenko M, Studzinski GP. Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen. *J Steroid Biochem Mol Biol*. 2019 Mar;187:166-173. doi: 10.1016/j.jsbmb.2018.11.015. PMID: 30508644.
175. Wang X, Dawod A, Nachliely M, Harrison JS, Danilenko M, Studzinski GP.

Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation. *J Cell Physiol.* 2019 Jun 27. doi: 10.1002/jcp.28996. PMID: 31245853

REVIEWS:

1. **Studzinski, GP.** Chapter on "Viral Transformation". In: *Growth, Nutrition, and Metabolism of Cells in Culture*, Vol. III, Edited by V.J. Cristofalo and G. Rothblat, Academic Press, 1977.
2. **Studzinski, GP,** Fischman, GJ, and Cholon, JJ. Changes in Nuclear Proteins During the Cell Cycle. In *Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells*, pg.191 198. Edited by Benjamin Drewinko and Ronald M. Humphrey, The Williams & Wilkins Company, 1977.
3. Lambert, MW, and **Studzinski, GP.** Methods for Assessment of DNase Activity. In: "Chromatin and Chromosomal Protein Research". Edited by Gary Stein, Janet Stein, and Lewis J. Kleinsmith, Vol. 19, *Methods in Cell Biology*, Series Editor David M. Prescott, pg. 43 49, Academic Press, 1978.
4. Studzinski, GP. Perspectives in Cell Biology. In: "Handbook of Cell Biology". Edited by L.M. Schwartz, Van Nostrand Rheinbold Co, 1980.
5. **Studzinski, GP.** Invited review. Oncogenes, growth, and the cell cycle: an overview. *Cell Tissue Kinet*, 22:405 425, 1989.
6. **Studzinski, GP,** Moore, DC, and Carter, DL. Suppressor genes; restraint of growth or of tumor progression? Editorial in: *Lab Investigation*, 63:279 282, 1990.
7. **Studzinski, GP,** McLane, JA, and Uskokovic, MR. Signaling pathways for vitamin D induced differentiation; implications for therapy of proliferative and neoplastic diseases. *Critical Reviews in Eukaryotic Gene Expression*, 4:279 312, 1993.
8. **Studzinski, GP,** and Godyn, JJ. The genetic basis for the emergence and progression of carcinoma of the breast. In: "Cancer of the Breast" 4th edition, Donegan WL and Spratt JL (Eds). WB Saunders Co. Chapter 14. pp 309 316, 1995.
9. **Studzinski, GP,** and Moore, DC. Vitamin D and retardation of cancer progression. In: "Nutrition and Cancer Prevention", Watson, RR & Mufti, SI. (Eds) CRC Press, Chapter 14, pp 257 282, 1995.
10. Ramachandra, S, and **Studzinski, GP.** Morphological and biochemical criteria of apoptosis. In: "Cell growth and Apoptosis: A Practical Approach" Studzinski, GP (Ed). Oxford University Press, New York, pp. 119 142, 1995.
11. Uskokovic, MR, **Studzinski, GP,** Reddy, SG. The 16 ene vitamin D analogs. In: "Vitamin D", Feldman, D, Glorieux, FH, Pike, JW. (Eds). Academic Press, San Diego, 1045 1070, 1997.
12. **Studzinski, GP,** Zhang, F, and Wang, QM. Multiple effects of 1,25 dihydroxyvitamin D₃ on the cell cycle traverse of human leukemia HL60 cells. In: "Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone". Norman, AW, Bouillon, R and Thomasset, M. (Eds). University of California Press, Riverside, CA, 397 404, 1997.
13. **Studzinski, GP,** and Harrison, L.E. Differentiation related changes in cell cycle traverse. Invited Review in: "International Review of Cytology" Jeon, KW (Ed), 189, pp. 1 58. Academic Press, San Diego, CA. 1999.
14. Coffman, FD, and **Studzinski, GP.** Differentiation related mechanisms which suppress DNA replication, *Exp. Cell Research*, 248:58 73, 1999.

15. Moore, DC and **Studzinski, GP**. Human leukemia cells as a model differentiation system. In: "Cell Growth, Differentiation and Senescence – A Practical Approach" Studzinski GP (Ed). Oxford University Press, Oxford, UK, 1999.
16. **Studzinski, GP**. Overview of apoptosis. In: "Apoptosis – A Practical Approach" Studzinski, GP (Ed). Oxford University Press, Oxford, UK, 1999.
17. **Studzinski, GP**. "Cell differentiation in vitro; model systems" in: Encyclopedia of Life Sciences, MacMillan Press, London, 2001.
18. **Studzinski, GP** and Harrison LE. The genetic influences on the emergence and progression of carcinoma of the breast. In: "Cancer of the Breast", 5th edition, Donegan WL and Spratt JL (Eds), WB Saunders Co., pp 169-180, 2002.
19. **Studzinski, GP**. A Compact Compendium on Caspases. *Cell Cycle*, 2:160-161, 2003.
20. **Studzinski, GP** and Danilenko, M. "Vitamin D Effects on Differentiation and Cell Cycle" in "Vitamin D" Second Edition. Eds: Feldman D. et al. 1635-1662, 2004.
21. Danilenko, M and **Studzinski, GP**. Enhancement by other compounds of the anti-cancer activity of Vitamin D3 and its analogs. *Exp Cell Res*, 339-358, 2004.
22. Demidenko ZN, **Studzinski, GP**, Blagosklonny, MV. From cytometry to cell cycle: a portrait of Zbigniew Darzynkiewicz. *Cell Cycle* 3:525-528, 2004.
23. Wang, Q, Harrison JS, Uskokovic, M, Kutner, A, **Studzinski, GP**. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. *Leukemia* 19:1812-7, 2005.
24. Marcinkowska, E, Wang, X, **Studzinski, GP**. C/EBP β ; a candidate for a major player in vitamin D-induced monocytic differentiation of human leukemia cells. In: "Vitamin D: New Research", Nova Science Publishers, Inc. New York Editor: Veronica D. Stolzt, chapter III: pp 25-39, 2006.
25. **Studzinski, GP**, Garay, E, Patel, R, Zhang, J, Wang, X. Vitamin D receptor signaling of monocytic differentiation in human leukemia cells; role of MAPK pathways in transcription factor activation. *Medicinal Chemistry*, 6:1267-1271, 2006.
26. Coffman, FD, **Studzinski, GP**. Somatic and Stem Cell Differentiation In Vitro: Model Systems. Encyclopedia of Life Sciences, 2008.
27. **Studzinski, GP** and Marcinkowska E. "Intracellular signaling for granulocytic and monocytic differentiation" In: Cell determination during hematopoiesis. Brown G and Ceredig R, Eds, Nova Publishers, NY, 2009.
28. Gocek E and **Studzinski GP**. "Vitamin D Differentiation in Cancer", *Critical Reviews in Clinical Laboratory Science*, 46:190-209, 2009. PMID 19650715.
29. Hughes, PJ, Marcinkowska, E, Gocek, E, **Studzinski, GP**, and Brown, G. Vitamin D3 –driven signals for myeloid cell differentiation-Implications for differentiation therapy. *Leukemia Research*, 34: 55-65, 2010. PMID:19811822.
30. **Studzinski, GP** and Danilenko, M. Vitamin D: Biochemistry, Nutrition and Roles. Nova Publishers, NY, 2009.
31. **Studzinski, GP**, Wang X, and Danilenko, M. DNA Damage Response: barrier or a path to tumor progression? *Cancer Biology and Therapy*, 9(3):253-5, Feb., 2010. PMID 20061811.

32. Gocek E, **Studzinski GP**. Induction of differentiation in cancer cells by vitamin D- derivatives". Chapter in: Vitamin D and Cancer, Trump D and Johnson C, Eds, in press, Springer, New York, 2010
33. **Studzinski, GP** and Danilenko, M. "Vitamin D cures cancer: Fact or Fiction ?" In: Vitamin D: Biochemistry, Nutrition and Roles. Nova Publishers, NY , 2009.
34. Gocek E, **Studzinski GP**. Genes encoding transcription factors have self-control; how important is this for cell differentiation? *Leukemia Res.* 36(6):672-4, 2012. PMID:22424711.
35. **Studzinski GP**. Editorial Commentary for *Leukemia Research and Treatment*.: "Differentiation and Cell Survival of Myeloid Leukemia Cells, , volume 2012 Article ID 370375, 2 pages, doi:10.1155/2012/370375, 2012.
- 36 Danilenko, M; Coffman, FD; and **Studzinski, GP**. Book Chapter for eLS, Wiley Online Library : A23699 (August 2012) Differentiation of Somatic Cells, Stem Cells and Stem Cell Variants: In Vitro Models. In: eLS 2012, [DOI: 10.1002/978047].
37. **Studzinski GP**, Brown G, Danilenko M, Hughes P, Marcinkowska E. *Leuk Res Treatment.* 2012;2012:370375. doi: 10.1155/2012/370375. Epub 2012 Jul 31. PMID: 23259065
38. Gocek E, Moulas AN, **Studzinski GP**: Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. *Crit Rev Clin Lab Sci.* 51: 125-37. 2014. PMID: 24446827.
39. Gocek E, **Studzinski GP**: The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy. *J Clin Med.* 4: 504-34., 2015. PMID:26239344
40. **Studzinski GP**, Harrison JS, Wang X, Sarkar S, Kalia V, Danilenko M: Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia. *J Cell Biochem.* 116:1500-12, 2015. PMID: 25694395.
41. Gocek E, **Studzinski GP**: DNA Repair in Despair-Vitamin D Is Not Fair. *J Cell Biochem.* 117: 1733-44. 2016. PMID: 27122067.

A. Patents Held **None**

1. *Title, U.S. Patent Number, Date of Issue, Inventors*

PRESENTATIONS

Note. I have been a faculty member of medical schools for over 54 years, and a member of New Jersey Medical School for over 40 years, and have over 200 total publications.. I am not in line for a promotion, so this form seems burdensome to senior faculty, with details no longer relevant, and/or impossible to recall.